<style face="normal" font="default" size="100%">722 Evaluation of the effects of pembrolizumab alone and in combination(s) with MDSC-targeting agents MK-0482 and MK-4830 on the native cancer patient TME via functional spatial profiling (CIVO®)</style>

Drupal-HighWire